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Abstract
Background: Aim of this prospective study was to predict response to neoadjuvant therapy in breast cancer
patients using an in vitro breast cancer spheroid model.
Methods: Three-dimensional spheroids were directly generated from fresh breast tumor biopsies of 78 patients
eligible for neoadjuvant therapy. Cell survival was measured after in vitro exposure to the equivalent therapeutic
agents in the breast cancer spheroid model. Treatment results in vitro were correlated with pathological complete
response (pCR, i.e. ypT0 ypN0) determined at surgery.
Results: A mean cell survival of 21.8 % was found in the breast cancer spheroid model for 22 patients with pCR
versus 63.8 % in 56 patients without pCR (P = .001). The area under the receiver operator characteristic curve to
predict pCR was 0.86 (95 % CI: 0.77 to 0.96) for cell survival in vitro compared to 0.80 (95 % CI: 0.70 to 0.90) for a
combined model of conventional factors (hormone- and HER2 receptor, and age). A cutoff at 35 % cell survival for
the spheroid model was proposed. Out of the 32 patients with values below this threshold, 21 patients (65.6 %)
and one patient (2.2 %) with a cell survival greater than 35 % achieved pCR respectively; (sensitivity 95.5 % (95 % CI:
0.86 to 1.00); specificity 80.4 % (95 % CI: 0.70 to 0.91)). Extent of residual disease positively correlated with increased
cell survival (P = .021).
Conclusion: The breast cancer spheroid model proved to be a highly sensitive and specific predictor for pCR after
neoadjuvant chemotherapy in breast cancer patients.
Keywords: Breast cancer, Neoadjuvant chemotherapy, Predicting treatment outcome, Cellular response to
anticancer drugs, Personalized medicine, in vitro diagnostics
Background
Multiple studies in breast cancer have shown that patho-
logical complete response (pCR) serves as a reliable
surrogate marker for progression-free survival, as well
as overall survival [1–6]. Despite all efforts, the rate
of pathological complete response (pCR) following neo-
adjuvant therapy for primary breast cancer remains low
at an average rate of 20-30 % [1, 7]. Efforts to maximize
the outcome of the standard neoadjuvant treatment have
been tested in numerous clinical trials, with variations in
dosing such as dose-dense or dose-intensified regimen
[8], or order of application of single-agent and combin-
ation treatment regimen [9, 10]. In addition, established
cytostatic agents or new drugs targeting HER2, angio-
genesis, or mammalian target of Rapamycin (mTOR)
have been combined to novel therapy strategies [11–16].
The application of targeted therapy in combination with
a taxane/anthracycine-based regimen with the addition
of carboplatin resulted in an increase of the rate of pCR
by 16.3 % in triple negative breast cancer patients [17].
Other trials have not yielded such promising results or
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the data obtained was inconclusive and did not warrant
changes in guideline recommendations. The addition of
capecitabine to a standard anthracycline/taxane-based
regimen [14], the sequence of paclitaxel and 5-FU/
anthracycline/cyclophosphamide combination therapy
[10], or the treatment of early non-responders with the
mTOR-inhibitor everolimus given simultaneously with
paclitaxel [15] did not show any improvement of pCR.
Encouraging developments have been made regarding
single and dual agent anti-HER2 blockade. This treat-
ment option raised the rate of pCR among women with
HER2-positive tumors up to 66.7 % [18–20]. Unfortu-
nately, among the HER2 positive patient population only
a limited proportion show a treatment response to
HER2 inhibition [21, 22]. In addition, only 20 % of all tu-
mors diagnosed are positive for this targetable biomarker
[23], leaving the majority of women with no further
treatment options aside from the standard chemotherapy
treatment. So far, no biomarker has been accepted for
routine use to accurately predict treatment outcome to
chemo- and/or anti-HER2-therapy.
Currently predictive diagnostic tests are available that
stratify patients to an individual treatment regimen using
a genetic or cellular approach. Assays based on the gen-
etic analysis of the tumor tissue make up the largest pro-
portion; some of these tests have already been validated
for specified subgroups in prospective trials [24–26].
However, no data that would indicate the most effective
treatment option is provided even though numerous
treatment options in breast cancer treatment are avail-
able [24, 27]. Cell-based chemosensitivity and chemore-
sistance assays, such as single-cell suspension and cell
monolayer assays [28–31], are currently not sufficiently
validated for clinical implementation [32]. Contrary to the
2-Dimensional (2D) cell culture models, 3-Dimensional
(3D) spheroid models reflect the tumor biology and tumor
microenvironment much more accurately [33–38]. The
spheroid-based assay proposed herein, was assessed as a
diagnostic tool to aid in the therapeutic decision-making.
The objective of the SpheroNEO study was to test
whether in vitro treatment results obtained in the breast
cancer spheroid model are associated with treatment
outcome in primary breast cancer patients undergoing
neoadjuvant therapy.
Methods
Starting from October 2009 until September 2012, 202
patients from 13 breast cancer centers in Germany were
enrolled in the SpheroNEO study. Written consent for
the trial was given by all applicable ethics committees.
An informed consent was obtained from all eligible
patients (Additional file 1). Patients 18 years or older
were eligible if a clinically confirmed case of invasive
breast cancer had been diagnosed and the use of
neoadjuvant chemotherapy was recommended. Patients
with a previous diagnosis and/or treatment of a malig-
nant disease, as well as patients with metastatic disease
were excluded.
Study design
The SpheroNEO study was designed as a prospective,
non-interventional cohort study. Tumor tissue from core
needle biopsies was obtained simultaneously for the
SpheroNEO study and histopathological diagnosis. Drugs
tested in the breast cancer spheroid model were recom-
mended by the treating physicians of the breast cancer
center at the time of the biopsy procedure. Results ob-
tained in the breast cancer spheroid model had no impact
on the treatment decision for the individual patient, and
treating physicians were blinded to the results of the la-
boratory test. A comparison of the therapeutic response in
vitro and clinical treatment outcome documented in the
pathological report was performed after all patients had
completed the neoadjuvant treatment followed by sur-
gery. Pathological complete response was defined as no
vital tumor in breast or axilla (pCR, i.e. ypT0 ypN0) de-
termined at surgery following the completion of
chemotherapy.
Breast cancer spheroid model
Fresh tumor biopsy samples were collected in freshly pre-
pared culture medium containing DMEM/F12-medium
(PAN), 10 % fetal calf serum (PAN), 2x MEM non-
essential amino acid solution (PAN), 2x MEM vitamin
solution NEAA, as well as a mixture of antibiotic/antifungal
compounds (0.26 μM Amphotericin B, Ampicillin
0.14 mM, Ciprofloxacin 7.54 μM) and shipped from
participating breast cancer centers to an external labora-
tory. All laboratory procedures and tests were performed
according to standardized, quality-controlled handling
procedures. The tumor samples underwent mechanical
and enzymatic digestion using an enzyme cocktail con-
taining Liberase TM, which consisted of a mixture of col-
lagenases and neutral protease enzymes (Roche, Penzberg
Germany). After determination of cell viability using the
trypan-blue exclusion test, the single cell suspension was
directly processed into breast cancer spheroids using a
modified liquid overlay technique [39, 40]. No red blood
cell lysis was performed. A training cohort of 14 breast
tumor biopsies was tested prior to study start, to optimize
the assay protocol. This was necessary since the previously
described liquid overlay method used RPMI culture
medium for basic cell line culture, this was replaced by
DMEM/F12 to better accommodate primary tumor cells.
The cell isolation procedure was also supplemented to
include additional washing steps to filter out cellular
debris. For this purpose the use of a cell strainer was
added to the cell isolation procedure as well.
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The spheroids were cultured for 48 h at 37 °C and 5 %
CO2 and treated with the recommended combination of
cytostatic agents using the peak plasma concentration of
each drug (ppc), see Table 1 for the utilized concentra-
tions and solvent controls. Spheroid formation was
verified and grade of compaction was documented
using bright field microscopy prior to drug treatment.
Medium was not changed during any time during the
spheroid culture. The duration of the drug treatment
was 96 h after which the treatment efficacy was
assessed using a standard assay measuring metabolic
activity (Promega, Mannheim Germany) to quantify
cell survival in vitro. Mean cell survival was expressed
as percent residual metabolic activity of the respective
solvent controls. Laboratory test results were available
after eight days.
Statistics
Sample size was estimated based on a 95 % true-positive
rate (TPR) and a true negative rate (TNR) of 90 % for
the breast cancer spheroid model. If 20 % of the patients
achieved pCR, a sample size of 70 was regarded as suffi-
cient to estimate both TPR and TNR with a lower limit
of the 95 % Clopper-Pearson interval greater than 66 %.
All results are reported from the intention-to-treat
analysis. Clinical and laboratory data was described sep-
arately for patients with and without pCR using appro-
priate measures of location and dispersion. Analyses of
the discriminatory power of the spheroid model and
traditional risk factors were based on receiver operating
characteristic (ROC) curves and the corresponding c sta-
tistics (areas under the ROC curves, AUC) calculated
using the SAS LOGISTIC procedure. Additional logistic
models were fit to estimate the role of the assay results
in the context of traditional risk factors, using forward
selection based on Wald tests on an alpha level of 5 %.
Since this frequently lead to a disproportion between the
number of the covariates and the sample size, the
analysis was replicated using penalized (lasso) logistic re-
gression in the R package “penalized”. DeLong 95 % con-
fidence intervals for the c statistics from the lasso
regression models were calculated using the R package
‘pROC’. The 95th percentile of the residual activity in
women with pCR was used as cut-off and the resulting
sensitivity and specificity and their 95 % confidence
limits are reported, calculation of the Youden Index re-
sulted in the same value. Laboratory data was correlated
with pCR using Pearson’s chi-square or Fisher’s exact
tests for categorical factors and t-tests for numerical var-
iables. The correlation between cell survival in vitro after
treatment and the size of residual tumor in the breast
(ypT) after neoadjuvant therapy was quantified using
Spearman's rank correlation coefficient. All hypotheses
tested were two-sided on an alpha level of 5 %. Analyses
were performed using the Statistical Analysis System
SAS, version 9.2 for Linux (SAS Institute, Cary, NC), as
well as R version 2.12.2 for Windows (The R Foundation
for Statistical Computing).
Results
A total of 202 patients were enrolled in the SpheroNEO
study. Figure 1 shows in detail the exclusion criteria for
the screened patients. The main clinical reasons for ex-
clusion were both related to choice of treatment. This
was due to the fact that at the time of biopsy the results
from the staging examinations were not yet available,
and a definitive treatment decision had not been made.
A total of 30 patients did not receive neoadjuvant treat-
ment as initially planned, instead undergoing primary
surgery followed by adjuvant treatment. The second main
reason for exclusion (n = 21) was the discrepancy between
clinical therapy and in vitro treatment, due to results from
final staging examinations or patient preferences.
As to the laboratory criteria, the main reason for ex-
clusion was the limited amount of cells isolated from the
biopsies. Due to the limited number of available cells no
additional assays were possible. This resulted in an in-
sufficient number of isolated cells (calculated minimum
of 2841 cells required; n = 13) or a metabolic activity
below threshold (n = 32). The mean duration from bi-
opsy procedure to the start of tissue preparation was
26.4 h (range 1.0 – 162.8 h). A breast cancer spheroid
assay was considered successful when the minimal meta-
bolic of the untreated controls measured at least 107.5
counts per second (cps). This threshold represented
twice the mean luminescence for the solvent controls
without cells. Results show that a minimum of four bi-
opsy cylinders with a mean total weight of 89.6 mg
(range 10.5 – 353.4 mg), were required to test a mini-
mum of three treatment combinations. The final analysis
included 78 patients, who qualified according to both
clinic and laboratory criteria.





Carboplatin 40.843 Go, Adjei, 1999 [53]
Cyclophosphamid 41.000 Egorin et al, 1989 [54]
Docetaxel 2.180 Baker et al, 2004 [55];
Bruno et al, 1998 [56]
Doxorubicin 1.640 Brana et al, 2014 [57]
Epirubicin 1.005 Reviewed in Fujimoto, 2007 [58]
Fluorouracil (5-FU) 100.000 Reviewed in Fujimoto, 2007 [58]
Paclitaxel 1.530 Gianni et al, 1995 [59]
Trastuzumab 88.000 Leyland-Jones, 2001 [60]
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Baseline characteristics of the SpheroNEO study cohort
Baseline characteristics are shown in Table 2. Age, clin-
ical tumor stage, tumor histology, and receptor status
were representative compared to previously published
larger cohorts [6, 41]. All except two patients received
taxane-based chemotherapy combined with either anthra-
cycline or carboplatin. All patients with HER2-positive
tumors received trastuzumab-based therapy (20.5 %).
Patient tumors were most frequently invasive ductal in
their histology (61 out of 78; 78.2 %) with a median
diameter of 2-5 cm (cT2; 45 out of 77; 58.4 %). Regarding
tumor biology, 64.5 % (49 out of 76) and 53.2 % (42 out
of 77) were positive for estrogen- and progesterone
receptor respectively.
The overall pCR rate for the SpheroNEO study cohort
was 28.2 % (22 out of 78). This rate is similar to other
studies where the majority of patients were also treated
with an anthracycline/taxane-based regimen [3, 42]. As
expected, pCR rate was higher in younger patients, hor-
mone receptor negative patients, as well as HER2-
positive patients (Table 2). Treatment non-adherence
defined as treatment discontinuation, dose-reduction, or
change of treatment regime resulted in a lower pCR rate
(p = .016).
Characterization of the breast cancer spheroid model
Tumor spheroids were directly derived from the tissue
samples without selecting any specific cell type [43]. Due
to the heterogeneity of the tissue, the breast cancer
spheroids varied between each patient in regard to cellu-
lar composition. The average size and compaction of the
spheroids was dependent on the number of cells per
spheroid and the cellular composition. Spheroid morph-
ology was classified as compact, intermediate, and loose
as previously published [40] and correlated with the pa-
tient characteristics. The spheroid morphology was not
effected by age (p = .678), cT Stadium (p = .064), nodal
status (p = .473), hormone receptor (p = .256) or HER2
status (p = .082), as well as Ki67 (p = .536). A lobular
histology also did not have an impact on spheroid
morphology, however only 8 cases were included in the
main analysis. The only factor which was associated with
significant differences in spheroid morphology was the
grading of the tumor (p = .009). High grade tumors
tended to form less compact spheroids while low grade
tumors generated more compact spheroids.
Predictive power of the breast cancer spheroid model for
treatment outcome
A significant difference in cell survival in vitro was
found in a comparison of patients achieving pCR versus
those who did not (p = .001; Fig. 2). A mean cell survival
of 21.8 % was found in the breast cancer spheroid model
for patients with pCR versus 63.8 % in non-pCR pa-
tients. For trastuzumab-based regimen a mean of 21.9 %
versus 45.4 % was seen in patients achieving or not
achieving pCR respectively (p = .085).
Hormone-receptor negative tumor samples (43.03 %,
p = .038) and HER2-positive tumor samples (30.7 %,
p < .0001) showed lower cell survival rates than hormone-
receptor-positive or HER2-negative tumor samples, re-
spectively (Table 3).
Fig. 1 Study flowchart depicting the screening process of the patients in the SpheroNEO cohort
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The predictive power of the breast cancer spheroid
model was analyzed in the context of established predic-
tors. The c statistic (area under the ROC curve) for the
treatment results in the breast cancer spheroid model
was 0.86 (Fig. 3a), which was superior to classic risk fac-
tors. The AUC for the standard clinical factors signifi-
cantly correlated with pCR in this cohort which were
hormone-receptor status, HER2, and age resulted in an
AUC of 0.80 (Fig. 3b). Simultaneous modelling of the
effects of the spheroid model and clinical predictors in
lasso regression models resulted in a slight increase of
the AUC to 0.91 when HER2 and the type of therapy
were considered, since patients receiving a trastuzumab-
Table 2 Baseline Characteristics and pCR Rates of the SpheroNEO
cohort
pCR
All Patients Yes No
Characteristics n % n % n % P
All Patients 78 100 22 28.2 56 71.8
Age at diagnosis, years .207
≤50 43 55.1 15 34.9 28 65.1
>50 35 44.9 7 20.0 28 80.0
Mean 51 21 - 78 46 21 - 65 53 25 - 78 .029
Range
Tumor stage .779
cT1/T2 56 72.7 16 28.6 40 71.4
cT3/4 21 27.3 5 23.8 16 76.2
Not documented 1 -
Nodal status 1.000
cN+ 42 54.5 12 28.6 30 71.4
cN- 35 45.5 10 28.6 25 71.4
Not documented 1 -
Grading .123
G1/2 41 53.9 8 19.5 33 80.5
G3 35 46.1 13 37.1 22 62.9
Not documented 2 -
Histologic type .449
Invasive ductal/other 70 89.7 21 30.0 49 70.0
Invasive lobular 8 10.0 1 12.5 7 87.5
HR status .001
ER+/PR+ 39 52.0 4 10.3 35 89.7
ER+/PR-/Unknown 10 13.3 7 70.0 3 30.0
ER-/unknown/PR+ 2 2.7 1 50.0 1 50.0
ER-/PR- 24 32.0 9 37.5 15 62.5
Not documented 3 -
HER2 status .001
Negative 59 78.7 11 18.6 48 81.4
Positive 16 21.3 10 62.5 6 37.5
Not documented 3 -
Drug Therapy .001
AC→ T 57 71.8 11 19.3 46 80.7
AC→ TH 9 11.5 8 88.9 1 11.1
TCbH 7 9.0 2 28.6 5 71.4
AC→ TCb 3 3.8 1 33.3 2 66.7
AC 2 3.6 0 0.0 2 100.0
Table 2 Baseline Characteristics and pCR Rates of the SpheroNEO
cohort (Continued)
Treatment adherence .018
Yes 60 76.9 21 35.0 39 65.0
No 18 23.1 1 5.6 17 94.4
Statistical tests for categorical factors were performed using the Pearson’s Χ2
test or Fisher’s exact test; tests for numerical factors were performed using
a t-test
PR, progesterone receptor; ER, estrogen receptor; HER2, human epidermal
growth factor receptor; pCR, pathologic complete response; A, anthracycline, T,
paclitaxel or docetaxel, C, cyclophosphamide; Cb, carboplatin, H, trastuzumab
Fig. 2 Dot histogram showing the mean cell survival of each tumor
sample following cytostatic treatment in the breast cancer spheroid
model. The results are grouped according to pCR. Each dot represents
one patient; triangles represent patients treated with trastuzumab-based
therapy. Proposed cutoff to predict pCR is shown at 35 % cell survival
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based therapy experienced higher pCR rates (Fig. 3c).
Patients who did not receive the planned therapy had a
lower rate of pCR (odds ratio = −2.94, P = .0126) The
AUC from the model considering assay results and treat-
ment adherence exhibited an AUC of 0.91 (Fig. 3d).
In addition to the pCR, correlation of cell survival with
the ypT-stage revealed that the breast cancer spheroid
model was significantly related to the gradual response
as seen in the surgical specimen after chemotherapy
(Fig. 4; Spearman’s rho = .311, p = .021).
A cutoff associated with pCR in the breast cancer
spheroid model was detected at 35 % cell survival. This
cutoff demonstrated a sensitivity of 95.5 % (21 out of 22)
and a specificity of 80.4 % (45 out of 56).
Correlation of clinical and pathological data with the
cutoff showed similar results in comparison to the re-
ported correlations with mean cell survival (Table 3).
Odds ratios calculated with clinical and laboratory
subgroups confirmed that HER2 status, treatment adher-
ence, and cutoff in the breast cancer spheroid model
significantly impact pCR (Table 4).
Discussion
The results of the SpheroNEO Study indicate that the in
vitro breast cancer spheroid model correctly identified
outcome for each treatment combination on an individual
patient basis. Tumor spheroids reflect the cancer biology
of the individual tumor more accurately compared to
traditional 2-D cell assays. A tumor spheroid model, such
as the one tested here, simulates the heterogeneity of cell
types, cell-cell interactions, and the microenvironment of
the patient tumor much more closely as compared to cell
monolayer assays [44–46], in addition, through the 3-D
structure a penetration barrier is formed allowing different
concentrations of cytostatic agent to reach each tumor
cell [47].
Cell-based chemosensitivity/chemoresistence assays
have been tested since the early 1970s, and the results
seemed initially promising [28, 32, 48, 49]. However,
implementation of these assays into the clinical routine
was not successful [32, 50, 51]. With an abundance of
available drugs and targeted therapies today, the number
of available treatment options for each patient is increasing,
and there is a necessity for a preclinical model to stratify
each patient to the optimal treatment option [52].
The aim of the present study was to introduce a pre-
clinical in vitro assay to tailor the best possible anti-tumor
treatment for breast cancer patients in the neoadjuvant
setting. There are some limitations regarding laboratory
methodology. The main difficulty was the minimal num-
ber of cells required for a reliable assay outcome. The
methodology had previously been established using surgi-
cal specimen from colorectal carcinoma patients, which
consistently yielded a greater number of isolated cells.
Adapting this method to the much smaller breast cancer
biopsies proved challenging, especially since the anatomy
of the breast is much more diverse in its tissue compo-
nents. This resulted in a wide range of total isolated cell
number per sample weight.
A second factor that influenced the drop-out rate of
patients was due to the timeline of the neoadjuvant
treatment. At the time of biopsy for the initial histo-
logical confirmation no final decision regarding the
chemotherapy regimen had been made for the respective
breast cancer patient. This explains the considerable
number of patients beginning a different neoadjuvant
treatment as initially planned, receiving primary surgery
with or without adjuvant treatment instead. The final
Table 3 Correlation of cell survival with Clinical and Pathological
Factors
Cutoff
Mean <35 % ≥35 %
Characteristics % P n % n % P
All Patients 32 41.0 46 59.0
Age at diagnosis, years .877 1.000
≤50 51.44 18 41.9 25 58.1
>50 52.61 14 40.0 21 60.0
Mean - 51 51 .817
Range - 21-76 25-78
Tumor stage .181 .603
cT1/T2 49.40 24 42.9 32 57.1
cT3/4 60.66 7 33.3 14 66.7
Nodal status .813 1.000
cN+ 50.41 17 40.5 25 59.5
cN- 52.20 15 42.9 20 57.1
Grading .339 .486
G1/2 55.34 15 36.6 26 63.4
G3 48.09 16 45.7 19 54.3
Not documented - -
Histologic type .569 .439
Ductal invasive/other 51.25 30 42.9 40 57.1
Lobular invasive 58.29 2 25.0 6 75.0
HR status .038 .042
ER+/PR+ 62.49 10 25.6 29 74.4
ER+/PR-/Unknown 36.10 7 70.0 3 30.0
ER-/unknown/PR+ 47.82 1 50.0 1 50.0
ER-/PR- 43.03 12 50.0 12 50.0
HER2 status .000 <.0001
Negative 58.34 17 28.8 42 71.2
Positive 30.70 13 81.3 3 18.8
PR, progesterone receptor; ER, estrogen receptor; HER2, human epidermal
growth factor receptor; pCR, pathologic complete response
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treatment decision is made in collaboration between
patient and physician, taking many clinical and non-
oncologic factors into account. Treatment non-adherence
was most frequent in older women, as well as in patients
with one or multiple comorbidities.
In vitro treatment efficacy results comparing standard
treatment combinations for all patients in this study
recapitulate treatment options as outlined for various
breast cancer subgroups in current guidelines. The high
standard deviations of these results reflect the heterogen-
eity of the patient subgroups. A total of six patients were
identified where more than one treatment combination
could be tested. The results of the breast cancer spheroid
model correctly identified the efficacy of the clinical treat-
ment combination by demonstrating a significantly lower
cell survival compared to other treatment combinations
tested. Interestingly at least two or more treatment
combinations proved equally effective in vitro, implying
Fig. 4 Box plot diagram showing mean cell survival in the breast cancer spheroid model after cytostatic treatment in comparison to the remaining
tumor as determined by the pathological assessment of the surgical specimen after chemotherapy. Proposed cutoff of 35 % is represented by
the dotted line. ypT0/ypN0 = 24.4 % (n = 19), ypTis =5.1 % (n = 4; ypN0 2 out of 3), ypT1 = 33.3 % (n = 26), ypT2 = 20.5 % (n = 16), ypT3 = 10.3 %
(n = 8), ypT4 = 1.3 % (n = 1), not documented (n = 4), * represents an outlier
Fig. 3 Receiver operator curves (ROC) displaying the sensitivity and specificity of (a) the breast cancer spheroid, (b) a multifactor model with baseline
predictive factors (ER, PR, HER2, and age) impacting pCR, (c) model combining the breast cancer spheroid model, HER2-Status and type of therapy,
and (d) breast cancer spheroid model combined with the factor of treatment adherence defined as treatment discontinuation, dose-reduction
or change of treatment. The resulting area under the curve (AUC) is displayed at the top of each curve
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that a decision between approved anthracyclines or
taxanes could be made according to each patient’s co-
morbidity or tolerability.
Furthermore, the breast cancer spheroid model showed
a predictive response to trastuzumab-based therapy prior
to histopathological confirmation of the HER2 status. In
the tumor samples tested in vitro with trastuzumab-based
therapy, a selective effect was seen. If the in vitro treat-
ment with trastuzumab showed no additional benefit as
compared to chemotherapy alone, the patients were histo-
logically confirmed HER2 negative (n = 5).
Conclusion
These preliminary analyses indicate that the breast can-
cer spheroid model is not only predictive but might also
be selective in discerning ineffective from effective treat-
ment options.
In order to validate the results from this explorative
study an interventional randomized controlled confirma-
tory study is planned, follow-up data will also be analyzed.
The cutoff as seen in this cohort of patients will be ana-
lyzed in regard to its validity and reliability in a larger
cohort of patients.
Additional file
Additional file 1: List of participating study sites and applicable
ethics committees.
Abbreviations
AUC: Area under the curve; CI: Confidence interval; cps: Counts per second;
HER2: Human epidermal growth factor 2; mTOR: Mammalian target of
rapamycin; pCR: Pathologic complete response; ppc: Peak plasma
concentration; ROC: Receiver operator curve; TNR: True negative rate;
TPR: True positive rate.
Competing interests
Employment or Leadership Position: Kathrin Halfter, Ilona Funke, Barbara
Mayer, SpheroTec GmbH, Gunter von Minckwitz, German Breast Group
Research GmbH
Consultant or Advisory Role: Gunter von Minckwitz , SpheroTec GmbH,
Astra Zeneca, Abbvie, Celgene, Pfizer, Roche, Illona Funke, SpheroTec GmbH,
Nina Ditsch, Astra Zeneca, Hans-Christian Kolberg, Novartis, Holger Fischer,
Roche Pharma
Stock Ownership: Ilona Funke, Barbara Mayer, SpheroTec GmbH, Gunter von
Minckwitz, German Breast Group Research GmbH
Honoraria: Nina Ditsch, Myriad Genetics, Holger Fischer, Roche Pharma,
Gunter von Minckwitz, Amgen, Astra Zeneca, Roche
Funding: Ilona Funke, Alexander Crispin, SpheroTec GmbH, Hans-Christian
Kolberg, Novartis and Amgen, Gunter von Minckwitz, Pfizer, GSK, Sanofi-Aventis,
Amgen, Roche, Novartis, Celgene, Teva, Boehringer-Ingelheim
Expert Testimony: None
Patents, Royalties, and Licenses: Ilona Funke, Barbara Mayer, SpheroTec
GmbH
Travel Expenses: Hans-Christian Kolberg, Novartis, GSK, Astra Zeneca and
Teva, Holger Fischer, Roche Pharma and Teva, Ilona Funke,Barbara Mayer,
SpheroTec GmbH
No other conflicts of interest exist. All remaining authors have declared no
conflicts of interest.
Authors’ contributions
The study was designed and a synopsis was drafted by BM, IF and ND. Data
acquisition and analysis of the laboratory and clinical data was done by KH
and AC at the University Clinic in Munich, Germany. Data interpretation was
performed by ND, AC, and GvM. ND, HCK, HF, TH, FEvK and IB contributed
significant numbers of patients for inclusion in the study. The first draft of
the study report was written by KH and reviewed and approved by all
co-authors before submission. Full access to the raw data was granted to BM
and AC at all times. All authors read and approved the final manuscript.
Acknowledgment
We would like to thank the patients who took part in the study, as well as the
participating study teams for their outstanding cooperation. We would also like
to thank Karin von Dehn-Rotfelser and Oliver Hoffman for their technical
assistance, as well as Jana Peplinski and Silvia Paulick for support in data
management.
Role of the funding source
The study was co-funded by academia and industry. The SpheroTec GmbH
performed the laboratory testing for all samples and provided the raw laboratory
data to the statistician (AC). The academic co-sponsor was not involved in any
phase of the completion of the final paper being submitted.
Author details
1Department of General, Visceral, Transplantation, Vascular and Thoraic
Surgery, Hospital of the University of Munich, Munich, Germany.
2Department of Obstetrics and Gynecology, Ludwig-Maximilians-University of
Munich, Munich, Germany. 3Marienhospital Bottrop, Bottrop, Germany.
4Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany. 5Klinikum St.
Marien Amberg, Amberg, Germany. 6Department of Obstetrics and
Gynecology, Klinikum Dritter Orden, Munich, Germany. 7Klinikum Landshut,
Landshut, Germany. 8GBG Forschungs GmbH, Neu-Isenburg and University
Women’s Hospital Frankfurt, Frankfurt, Germany. 9SpheroTec GmbH,
Martinsried, Germany. 10IBE LMU, Department of Obstetrics and Gynecology,
Technical University of Munich, Klinikum Starnberg, Leopoldina Krankenhaus
der Stadt Schweinfurt, Markus Krankenhaus Frankfurt, Klinikum Nürnberg,
Städtisches Klinkum Karlsruhe, Klinikum Harlaching, Munich, Germany.
Received: 9 September 2014 Accepted: 16 June 2015
References
1. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA,
et al. Definition and impact of pathologic complete response on prognosis
after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
J Clin Oncol. 2012;30(15):1796–804.
2. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al.
Pathologic complete response predicts recurrence-free survival more effectively
by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN
6657. J Clin Oncol. 2012;30(26):3242–9.
3. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A,
et al. Preoperative chemotherapy: updates of National Surgical Adjuvant
Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol.
2008;26(5):778–85.
4. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al.
Clinical course of breast cancer patients with complete pathologic primary
tumor and axillary lymph node response to doxorubicin-based neoadjuvant
chemotherapy. J Clin Oncol. 1999;17(2):460–9.
Table 4 Odds ratios for the clinical and laboratory variables
impacting pCR in a multivariable model
Characteristics Odds ratio 95 % CI P
Cell survival cutoff (>35 %/≤ 35 %) 0.011 0.001 – 0.096 .0001
Treatment adherence (no/yes) 0.115 0.014 – 0.925 .0421
HR status (pos/neg) 0.513 0.180 – 1.465 .2123
HER2 status (neg/pos) 0.167 0.050 – 0.560 .0037
Age (>50/≤50 years) 0.501 0.177 – 1.417 .1505
Halfter et al. BMC Cancer  (2015) 15:519 Page 8 of 10
5. Prowell TM, Pazdur R. Pathological complete response and accelerated drug
approval in early breast cancer. N Engl J Med. 2012;366(26):2438–41.
6. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al.
Pathological complete response and long-term clinical benefit in breast
cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.
7. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, et al.
Pathological complete response after preoperative systemic therapy and
outcome: relevance of clinical and biologic baseline features. Breast Cancer
Res Treat. 2010;124(3):689–99.
8. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al.
Intensified neoadjuvant chemotherapy in early-responding breast cancer:
phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100(8):552–62.
9. Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of
the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant
sequential epirubicin, cyclophosphamide, and paclitaxel for women with
high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial
randomised phase 3 trial. Lancet Oncol. 2014;15(2):201–12.
10. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC,
et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by
paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by
FEC-75 plus trastuzumab as neoadjuvant treatment for patients with
HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
Lancet Oncol. 2013;14(13):1317–25.
11. Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy
in breast cancer. Eur J Pharmacol. 2013;717(1-3):58–66.
12. Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, et al.
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy
in 678 triple-negative primary breast cancers; results from the geparquinto
study (GBG 44). Ann Oncol. 2013;24(12):2978–84.
13. Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sanchez-Rovira P, et al.
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast
cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014;110(5):1139–47.
14. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al.
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant
treatment in patients with primary breast cancer: phase III GeparQuattro
study. Ann Oncol. 2010;28(12):2015–23.
15. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, et al.
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer
patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)
+/- bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Eur J Cancer. 2013;49(10):2284–93.
16. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al.
Lapatinib versus trastuzumab in combination with neoadjuvant
anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44):
a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44.
17. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive
early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet
Oncol. 2014;15(7):747–56.
18. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al.
Significantly higher pathologic complete remission rate after neoadjuvant
therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results
of a randomized trial in human epidermal growth factor receptor 2-positive
operable breast cancer. J Clin Oncol. 2005;23(16):3676–85.
19. Dent S, Oyan B, Honig A, Mano M, Howell S. HER2-targeted therapy in
breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev.
2013;39(6):622–31.
20. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and
safety of neoadjuvant pertuzumab and trastuzumab in women with locally
advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a
randomised multicentre, open-label, phase 2 trial. Lancet Oncol.
2012;13(1):25–32.
21. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast
Cancer. Clin Cancer Res. 2009;15(24):7479–91.
22. Wilson S, Chia S. New agents in locally advanced breast cancer. Curr Opin
Support Palliat Care. 2014;8(1):64–9.
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use
of chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
24. Kittaneh M, Montero AJ, Gluck S. Molecular Profiling for Breast Cancer: A
Comprehensive Review. Biomark Cancer. 2013;5:61–70.
25. Azim Jr HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al.
Elucidating prognosis and biology of breast cancer arising in young women
using gene expression profiling. Clin Cancer Res. 2012;18(5):1341–51.
26. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and
benefit of chemotherapy in women with node-negative, estrogen
receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.
27. Harbeck N, Sotlar K, Wuerstlein R, Doisneau-Sixou S. Molecular and protein
markers for clinical decision making in breast cancer: Today and tomorrow.
Cancer Treat Rev. 2014;40(3):434–44.
28. Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, Backner A, et al.
Feasibility assessment of a chemoresponse assay to predict pathologic
response in neoadjuvant chemotherapy for breast cancer patients.
Anticancer Res. 2008;28(3B):1733–40.
29. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival
outcomes in patients with recurrent ovarian cancer who were treated with
chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol.
2003;189(5):1301–7.
30. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug
resistance with an in vitro assay using suprapharmacologic drug exposures.
J Natl Cancer Inst. 1990;82(7):582–8.
31. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ,
et al. Outcome of ATP-based tumor chemosensitivity assay directed
chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC
Cancer. 2003;3:19.
32. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, et al.
American Society of Clinical Oncology clinical practice guideline update on
the use of chemotherapy sensitivity and resistance assays. J Clin Oncol.
2011;29(24):3328–30.
33. Vidi PA, Bissell MJ, Lelievre SA. Three-dimensional culture of human
breast epithelial cells: the how and the why. Methods Mol Biol.
2013;945:193–219.
34. Nagelkerke A, Bussink J, Sweep FC, Span PN. Generation of multicellular
tumor spheroids of breast cancer cells: how to go three-dimensional. Anal
Biochem. 2013;437(1):17–9.
35. Weiswald LB, Richon S, Massonnet G, Guinebretiere JM, Vacher S, Laurendeau I,
et al. A short-term colorectal cancer sphere culture as a relevant tool for human
cancer biology investigation. Br J Cancer. 2013;108(8):1720–31.
36. Napolitano AP, Dean DM, Man AJ, Youssef J, Ho DN, Rago AP, et al.
Scaffold-free three-dimensional cell culture utilizing micromolded nonadhesive
hydrogels. BioTechniques. 2007;43(4):494. 496-500.
37. Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H, Tsujii M, et al. Retaining
cell-cell contact enables preparation and culture of spheroids composed of
pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A.
2011;108(15):6235–40.
38. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput
3D spheroid culture and drug testing using a 384 hanging drop array. Analyst.
2011;136(3):473–8.
39. Yuhas JM, Li AP, Martinez AO, Ladman AJ. A simplified method for production
and growth of multicellular tumor spheroids. Cancer Res. 1977;37(10):3639–43.
40. Mayer B, Klement G, Kaneko M, Man S, Jothy S, Rak J, et al. Multicellular
gastric cancer spheroids recapitulate growth pattern and differentiation
phenotype of human gastric carcinomas. Gastroenterology.
2001;121(4):839–52.
41. Angelucci D, Tinari N, Grassadonia A, Cianchetti E, Ausili-Cefaro G, Iezzi L, et al.
Long-term outcome of neoadjuvant systemic therapy for locally advanced
breast cancer in routine clinical practice. J Cancer Res Clin Oncol.
2013;139(2):269–80.
42. Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, et al.
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense,
dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a
standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/-
darbepoetin alfa in primary breast cancer–results at the time of surgery.
Ann Oncol. 2011;22(9):1988–98.
43. Hoffmann OI, Ilmberger C, Magosch S, Joka M, Jauch KW, Mayer B. Impact of the
spheroid model complexity on drug response. J Biotechnol. 2015;205:14–23.
44. Kim S, Alexander CM: Tumorsphere assay provides more accurate prediction
of in vivo responses to chemotherapeutics. Biotechnology letters
2013;36:481–488.
45. Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and
challenges for use of tumor spheroids as models to test drug delivery and
efficacy. J Control Release. 2012;164(2):192–204.
Halfter et al. BMC Cancer  (2015) 15:519 Page 9 of 10
46. Herrmann D, Conway JR, Vennin C, Magenau A, Hughes WG, Morton JP,
et al. Three-dimensional cancer models mimic cell-matrix interactions in the
tumour microenvironment. Carcinogenesis. 2014;35(8):1671–9.
47. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev
Cancer. 2006;6(8):583–92.
48. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy
selected by in vitro drug sensitivity testing for patients with cancer. J Clin
Oncol. 1999;17(5):1625–31.
49. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH. Chemosensitivity
testing of human solid tumors. A review of 1582 assays with 258 clinical
correlations. Cancer. 1984;53(6):1240–5.
50. Rutherford T, Orr Jr J, Grendys Jr E, Edwards R, Krivak TC, Holloway R, et al.
A prospective study evaluating the clinical relevance of a chemoresponse
assay for treatment of patients with persistent or recurrent ovarian cancer.
Gynecol Oncol. 2013;131(2):362–7.
51. Nagourney RA, Blitzer JB, Shuman RL, Asciuto TJ, Deo EA, Paulsen M, et al.
Functional profiling to select chemotherapy in untreated, advanced or
metastatic non-small cell lung cancer. Anticancer Res. 2012;32(10):4453–60.
52. Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, et al.
Critical research gaps and translational priorities for the successful prevention
and treatment of breast cancer. Breast Cancer Res. 2013;15(5):R92.
53. Go RS, Adjei AA. Review of the comparative pharmacology and clinical
activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409–22.
54. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA. A
limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer
Res. 1989;49(11):3129–33.
55. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, et al.
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Clin Cancer Res. 2004;10(6):1976–83.
56. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom
AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in
phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187–96.
57. Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, et al. A phase I trial of
pantoprazole in combination with doxorubicin in patients with advanced
solid tumors: evaluation of pharmacokinetics of both drugs and tissue
penetration of doxorubicin. Investig New Drugs. 2014;32(6):1269–77.
58. Fujimoto S. Promising antitumor activity of a novel quinoline derivative,
TAS-103, against fresh clinical specimens of eight types of tumors measured
by flow cytometric DNA analysis. Biol Pharm Bull. 2007;30(10):1923–9.
59. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, et al. Nonlinear
pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/
pharmacodynamic relationships in humans. J Clin Oncol. 1995;13(1):180–90.
60. Leyland-Jones B. Dose scheduling–Herceptin. Oncology. 2001;61 Suppl 2:31–6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Halfter et al. BMC Cancer  (2015) 15:519 Page 10 of 10
